Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 10:00 | 2026-09-11 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Heshmatpour Amir F | Director, Officer, 10% owner | BUY | $3.67 | 37,000 | $135,620 | 3,133,000 |
| 2026-09-12 00:14 | 2026-09-10 | AARD | Aardvark Therapeutics, Inc. | Sun Nelson | Officer | SELL | $5.15 | 76,754 | $394,961 | 35,475 |
| 2026-09-11 23:45 | 2026-09-09 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Director | SELL | $6.02 | 1,108 | $6,675 | 624,765 |
| 2026-09-11 23:12 | 2026-09-11 | CYTK | CYTOKINETICS INC | Landry Robert E | Director | SELL | $74.66 | 1,000 | $74,660 | 9,184 |
| 2026-09-11 21:20 | 2026-09-09 | PTCT | PTC THERAPEUTICS, INC. | SCHMERTZLER MICHAEL | Director | SELL | $67.59 | 20,000 | $1,351,804 | 1,316,594 |
| 2026-09-11 20:57 | 2026-09-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John | Director, Officer | SELL | $538.65 | 11,583 | $6,239,198 | 197,746 |
| 2026-09-11 20:26 | 2026-09-10 | AUPH | Aurinia Pharmaceuticals Inc. | Robertson Stephen P. | Officer | SELL | $15.95 | 11,939 | $190,427 | 588,848 |
| 2026-09-11 20:30 | 2026-09-09 | TYRA | Tyra Biosciences, Inc. | Verjee Rehan | Director | BUY | $20.58 | 972 | $20,000 | 972 |
| 2026-09-11 20:30 | 2026-09-09 | NBP | NovaBridge Biosciences | Cao Sean Wuxiong | Officer | SELL | $0.74 | 107,978 | $79,904 | 266,467 |
| 2026-09-11 20:34 | 2026-09-10 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $502.35 | 9,500 | $4,772,296 | 324,443 |
| 2026-09-11 20:10 | 2026-09-10 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer | OPT+S | $17.62 | 10,185 | $179,457 | 39,900 |
| 2026-09-11 20:04 | 2026-09-09 | INSM | INSMED Inc | Brennan David R | Director | SELL | $124.00 | 25,000 | $3,100,000 | 39,238 |
| 2026-09-11 20:05 | 2026-09-10 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Director | OPT+S | $67.31 | 20,000 | $1,346,106 | 91,500 |
| 2026-09-11 20:05 | 2026-08-08 | AZN | ASTRAZENECA PLC | Sharma Mani | Officer | BUY | $160.57 | 20 | $3,249 | 19,288 |
| 2026-09-11 16:25 | 2026-09-09 | PHVS | Pharvaris N.V. | Glassman Robert | Director | OPT+S | $37.55 | 8,000 | $300,396 | 10,500 |
| 2026-09-11 15:29 | 2026-09-07 | KMDA | KAMADA LTD | Tsur David | Director | SELL | $8.26 | 177,173 | $1,463,732 | 430,756 |
| 2026-09-11 15:07 | 2026-09-09 | AQST | Aquestive Therapeutics, Inc. | Korczynski Sherry | Officer | OPT+S | $5.22 | 8,750 | $45,675 | 235,689 |
| 2026-09-11 13:04 | 2026-09-08 | CYBN | CYBIN INC. | Glavine Paul | Officer | BUY | $12.47 | 100,000 | $1,247,190 | 4,271,252 |
| 2026-09-11 13:01 | 2026-09-08 | CYBN | CYBIN INC. | So Eric H. L. | Director, Officer | BUY | $12.39 | 100,000 | $1,238,670 | 4,465,014 |
| 2026-09-11 12:00 | 2026-09-10 | ANIX | Anixa Biosciences Inc | KUMAR AMIT | Director, Officer | BUY | $2.76 | 5,000 | $13,800 | 662,000 |
| 2026-09-11 11:30 | 2026-09-09 | RLMD | RELMADA THERAPEUTICS, INC. | TRAVERSA SERGIO | Director, Officer | BUY | $4.14 | 200,000 | $828,000 | 1,500,000 |
| 2026-09-11 11:30 | 2026-09-09 | RLMD | RELMADA THERAPEUTICS, INC. | Shenouda Maged | Officer | BUY | $4.22 | 200,000 | $844,000 | 1,000,000 |
| 2026-09-10 20:23 | 2026-09-08 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $22.90 | 17,500 | $400,715 | 181,641 |
| 2026-09-10 20:05 | 2026-09-08 | KRRO | Korro Bio, Inc. | Dolan Oliver | Officer | SELL | $13.51 | 7,353 | $99,368 | 16,246 |
| 2026-09-10 20:05 | 2026-09-08 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% owner | BUY | $2.09 | 15,229 | $31,896 | 2,775,229 |
| 2026-09-11 01:17 | 2026-09-08 | PTGX | Protagonist Therapeutics, Inc | PATEL DINESH V PH D | Director, Officer | OPT+S | $145.92 | 125,000 | $18,240,563 | 522,968 |
| 2026-09-11 01:00 | 2026-09-08 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Director | OPT+S | $39.90 | 20,000 | $798,000 | 42,963 |
| 2026-09-10 23:37 | 2026-09-10 | LYEL | Lyell Immunopharma, Inc. | Shook David | Officer | SELL | $12.70 | 500 | $6,350 | 20,423 |
| 2026-09-10 23:24 | 2026-09-08 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | Officer | SELL | $25.03 | 9,989 | $249,986 | 116,182 |
| 2026-09-10 22:10 | 2026-09-10 | CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | BUY | $0.05 | 3,500 | $175 | 9,400,556 |
| 2026-09-10 20:37 | 2026-09-09 | BMY | BRISTOL MYERS SQUIBB CO | Massacesi Cristian | Officer | SELL | $64.57 | 6,249 | $403,498 | 18,748 |
| 2026-09-10 20:49 | 2026-09-08 | ONC | BeOne Medicines Ltd. | Wang Xiaodong | Director | OPT+S | $349.10 | 38,287 | $13,366,091 | 0 |
| 2026-09-10 20:31 | 2026-09-09 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $501.84 | 9,500 | $4,767,468 | 324,443 |
| 2026-09-10 20:33 | 2026-09-08 | JAZZ | Jazz Pharmaceuticals plc | GALA RENEE D | Officer | SELL | $243.03 | 2,000 | $486,060 | 143,394 |
| 2026-09-10 17:29 | 2026-08-19 | ELTP | ELITE PHARMACEUTICALS INC /NV/ | Dash Barry H | Director | BUY | $0.29 | 30,000 | $8,610 | 3,265,555 |
| 2026-09-10 11:30 | 2026-09-09 | GRCE | Grace Therapeutics, Inc. | Kohli Prashant | Director, Officer | BUY | $2.14 | 100,000 | $214,000 | 121,357 |
| 2026-09-10 10:19 | 2026-09-03 | CYBN | CYBIN INC. | Glavine Paul | Officer | BUY | $11.78 | 100,000 | $1,178,280 | 4,171,252 |
| 2026-09-10 10:21 | 2026-09-04 | CYBN | CYBIN INC. | So Eric H. L. | Director, Officer | BUY | $12.09 | 100,000 | $1,208,900 | 4,365,014 |
| 2026-09-10 01:39 | 2026-09-08 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Director | SELL | $10.55 | 96,131 | $1,014,028 | 2,025,493 |
| 2026-09-10 01:39 | 2026-09-04 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Director | BUY | $10.87 | 986,721 | $10,726,249 | 2,298,783 |
| 2026-09-09 23:39 | 2026-09-04 | BLTE | BELITE BIO, INC | Lin Yu-Hsin | Director, Officer | SELL | $190.00 | 100,435 | $19,082,550 | 70,134 |
| 2026-09-09 23:38 | 2026-09-04 | BLTE | BELITE BIO, INC | Chuang Hao-Yuan | Director, Officer | SELL | $189.98 | 67,395 | $12,803,527 | 26,038 |
| 2026-09-09 23:18 | 2026-09-04 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $68.88 | 9,976 | $687,160 | 536,876 |
| 2026-09-09 23:23 | 2026-09-04 | TRDA | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $7.33 | 259,837 | $1,905,774 | 3,885,115 |
| 2026-09-09 23:24 | 2026-09-04 | TRDA | Entrada Therapeutics, Inc. | MPM BIOVENTURES 2018, L.P. | 10% owner | SELL | $7.33 | 259,837 | $1,905,774 | 3,885,115 |
| 2026-09-09 22:43 | 2026-07-16 | CVSI | CV Sciences, Inc. | CHEEVER CHARLIE E III | 10% owner | BUY | $0.02 | 5,740,816 | $114,816 | 26,648,711 |
| 2026-09-09 21:47 | 2026-09-01 | CYBN | CYBIN INC. | So Eric H. L. | Director, Officer | BUY | $11.81 | 95,000 | $1,121,475 | 4,265,014 |
| 2026-09-09 21:04 | 2026-09-08 | ASND | Ascendis Pharma A/S | Bodenhoff Mads | Officer | OPT+S | $270.19 | 3,000 | $810,570 | 0 |
| 2026-09-09 21:12 | 2026-09-04 | HRMY | Harmony Biosciences Holdings, Inc. | Budur Kumar | Officer | OPT+S | $42.80 | 33,954 | $1,453,170 | 13,115 |
| 2026-09-09 20:23 | 2026-09-04 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | SELL | $79.96 | 1,689 | $135,052 | 13,427 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.